Literature DB >> 11401992

Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine.

O Pérez1, M Lastre, J Lapinet, G Bracho, M Díaz, C Zayas, C Taboada, G Sierra.   

Abstract

This report explores the participation of some afferent mechanisms in the immune response induced by the Cuban anti-meningococcal vaccine VA-MENGOC-BC. The induction of delayed-type hypersensitivity in nursing babies and lymphocyte proliferation after immunization is demonstrated. The presence of gamma interferon IFN-gamma and interleukin-2 (IL-2) mRNAs but absence of IL-4, IL-5, and IL-10 mRNAs were observed in peripheral blood mononuclear cells from immunized subjects after in vitro challenge with outer membrane vesicles. In addition, some effector functions were also explored. The presence of opsonic activity was demonstrated in sera from vaccinees. The role of neutrophils as essential effector cells was shown. In conclusion, we have shown that, at least in the Cuban adult population, VA-MENGOC-BC induces mechanisms with a T-helper 1 pattern in the afferent and effector branches of the immune response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401992      PMCID: PMC98525          DOI: 10.1128/IAI.69.7.4502-4508.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.

Authors:  B A Perkins; K Jonsdottir; H Briem; E Griffiths; B D Plikaytis; E A Hoiby; E Rosenqvist; J Holst; H Nokleby; F Sotolongo; G Sierra; H C Campa; G M Carlone; D Williams; J Dykes; D Kapczynski; E Tikhomirov; J D Wenger; C V Broome
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

2.  Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.

Authors:  M Ryan; G Murphy; E Ryan; L Nilsson; F Shackley; L Gothefors; K Oymar; E Miller; J Storsaeter; K H Mills
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

3.  An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues.

Authors:  J Finne; D Bitter-Suermann; C Goridis; U Finne
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

4.  Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors:  F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

5.  Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine.

Authors:  E R van der Voort; H van Dijken; B Kuipers; J van der Biezen; P van der Ley; J Meylis; I Claassen; J Poolman
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

6.  Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells.

Authors:  M Ryan; G Murphy; L Gothefors; L Nilsson; J Storsaeter; K H Mills
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

7.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Authors:  T R Mosmann; H Cherwinski; M W Bond; M A Giedlin; R L Coffman
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

Review 8.  Meningococcal disease: still with us.

Authors:  H Peltola
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

9.  Human immunity to the meningococcus. II. Development of natural immunity.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  11 in total

1.  Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination.

Authors:  Fredrik Oftung; Gro Ellen Korsvold; Audun Aase; Lisbeth M Næss
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.

Authors:  Monica Konar; Dan M Granoff
Journal:  Blood       Date:  2017-06-19       Impact factor: 22.113

Review 3.  Immune modulation by bacterial outer membrane vesicles.

Authors:  Maria Kaparakis-Liaskos; Richard L Ferrero
Journal:  Nat Rev Immunol       Date:  2015-05-15       Impact factor: 53.106

4.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Combined meningococcal serogroup A and W135 outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A.

Authors:  Belkis Romeu; Miriam Lastre; Luis García; Bárbara Cedré; Aleida Mandariote; Mildrey Fariñas; Reynaldo Oliva; Einar Rosenqvist; Oliver Pérez
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

6.  Cross-protection induced by VA-MENGOC-BC® vaccine.

Authors:  Rolando Felipe Ochoa-Azze
Journal:  Hum Vaccin Immunother       Date:  2018-02-26       Impact factor: 3.452

Review 7.  Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines.

Authors:  Helen Petousis-Harris; Fiona J Radcliff
Journal:  Front Immunol       Date:  2019-04-09       Impact factor: 7.561

8.  Cross-reactivity with Brazilian strains of Neisseria meningitidis B after immunization with outer membrane vesicles.

Authors:  Gabriela Trzewikoswki de Lima; Amanda Izeli Portilho; Elizabeth De Gaspari
Journal:  Ther Adv Vaccines Immunother       Date:  2019-12-11

9.  New proteoliposome vaccine formulation from N. meningitidis serogroup B, without aluminum hydroxide, retains its antimeningococcal protectogenic potential as well as Th-1 adjuvant capacity.

Authors:  Beatriz Tamargo; Yanet Márquez; Wendy Ramírez; Bárbara Cedré; Manuel Fresno; Gustavo Sierra
Journal:  BMC Immunol       Date:  2013-02-25       Impact factor: 3.615

Review 10.  Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform.

Authors:  Oliver Pérez; Belkis Romeu; Osmir Cabrera; Elizabeth González; Alexander Batista-Duharte; Alexis Labrada; Rocmira Pérez; Laura M Reyes; Wendy Ramírez; Sergio Sifontes; Nelson Fernández; Miriam Lastre
Journal:  Front Immunol       Date:  2013-12-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.